General Partner

Actavis plc (NYSE: ACT) completed on March 17, 2015 the acquisition of Allergan, creating a diversified global pharmaceutical company. The combined company is focused on developing new medicines that address unmet medical needs in critical therapeutic areas, as well as increasing global access to high-quality, affordable medicines.

The Actavis + Allergan Brand portfolio features six franchises in key therapeutic categories, including Dermatology and Aesthetics; CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular and Infectious Disease.

Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

The Actavis + Allergan Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The combined company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.


2nd CME CNS, Athens

Athens, May 22-23, 2015

1st CME CNS 2014

Summary, lectures, archive


Live streaming and an online archive of the International Postgraduate Schools